Why Is GREENWICH LIFESCIENC (GLSI) Stock Moving Today?

Greenwich LifeSciences (GLSI) stock is moving today following a key regulatory development in Europe. The company announced approval from the European Medicines Agency to combine HLA-A*02 and non-HLA-A*02 participants in its FLAMINGO-01 Phase III trial. This change allows for a more flexible trial design and could accelerate data collection. The stock opened slightly lower but has since risen to $20.54, up 5.1% from the prior close.

What Happened

Greenwich LifeSciences disclosed that the European Medicines Agency has approved the inclusion of both HLA-A*02 and non-HLA-A*02 participants in its FLAMINGO-01 trial. This approval allows the company to use a single manufacturing process for its investigational therapy, GP2, across all participants in the European arm of the trial. The change eliminates the need for separate patient cohorts based on HLA status, streamlining the trial and potentially reducing delays. The company also noted that this decision aligns with its broader strategy to optimize the trial for global regulatory submissions.

The stock opened at $19.44, a 0.5% gap down from the previous close, but quickly reversed to post a 5.1% gain by the end of the morning session. The move follows recent updates on the trial, including the publication of an abstract and poster at the 2026 ASCO Annual Meeting and ongoing progress in the late-stage breast cancer immunotherapy trial.

What The Data Shows

The stock has traded between $7.78 and $34.10 over the past 52 weeks. The current intraday session has seen a high of $20.73 and a low of $19.44, with the last price at $20.54. Volume remains at 0.0M shares, which is 0.0x the 3-month average. The stock has a market cap of $272.6M and a beta of 1.39, indicating higher volatility than the market. The company remains unprofitable, with a trailing twelve-month EPS of -1.60.

What To Watch

The company has a history of missing earnings estimates, including a Q4 EPS of -0.58, which fell short of the -0.31 estimate. Investors should monitor upcoming developments in the FLAMINGO-01 trial, including interim data or enrollment updates. The coverage breadth of the company is currently limited to two stories in the past 36 hours, suggesting the market is still processing the regulatory news.